AI Article Synopsis
Article Abstract
During the menopausal transition, women experience a number of symptoms due to declining estrogen levels, including vasomotor symptoms and vulvar and vaginal atrophy (VVA). Unlike vasomotor symptoms, vaginal dryness and dyspareunia, the main symptoms of VVA, typically worsen without treatment and can significantly impact the quality of life. Up to 60% of postmenopausal women may be affected by VVA, but many women unfortunately do not seek treatment due to embarrassment or other factors. After 20+ years in development, ospemifene (Osphena™) was approved by the US Food and Drug Administration in 2013 for treatment of moderate-to-severe dyspareunia associated with VVA due to menopause. As the first non-hormonal alternative to estrogen-based products for this indication, the approval of ospemifene represents a significant milestone in postmenopausal women's health. Ospemifene is a non-steroidal estrogen receptor agonist/antagonist, also known as a selective estrogen receptor modulator (SERM), from the same chemical class as the breast cancer drugs tamoxifen and toremifene. Unlike other selective estrogen receptor modulators, ospemifene exerts a strong, nearly full estrogen agonist effect in the vaginal epithelium, making it well suited for the treatment of dyspareunia in postmenopausal women. Results of Phase III clinical trials showed that ospemifene significantly improved the vaginal maturation index (decreased parabasal cells and increased superficial cells), decreased vaginal pH, and decreased severity of the self-identified most bothersome symptom (dyspareunia or vaginal dryness) compared to placebo. Long-term safety studies revealed that 60 mg ospemifene given daily for 52 weeks was well tolerated and was not associated with any endometrium or breast-related safety concerns. This review discusses the preclinical and clinical data supporting the use of ospemifene for the treatment of dyspareunia associated with VVA due to menopause and provides an overview of its clinical safety.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4235480 | PMC |
| http://dx.doi.org/10.2147/CIA.S73753 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of sexual function between laparoscopic lateral suspension and laparoscopic sacrocervicopexy with the use of the PISQ-IR questionnaire.
Front Med (Lausanne)
December 2024
Hôpitaux Universitaires de Genève (HUG), Geneva, Switzerland.
Introduction And Hypothesis: We aimed to analyze the quality of sexual life of patients with apical vaginal wall prolapse who had undergone laparoscopic lateral suspension (LLS) and laparoscopic sacrocolpopexy (LSC).
Methods: We performed a secondary analysis of sexual outcomes of a previous randomized control trial comparing LLS and LSC in 89 women with symptomatic POP stage ≥ II. We evaluated sexually active (SA) and non-sexually active women (NSA) using the Pelvic Organ Prolapse/Incontinence Sexual Questionnaire-IUGA-Revised (PISQ-IR).
This is the case of a 30-year-old nulliparous patient with a complete uterine septum, double cervix and non- obstructive longitudinal vaginal septum (Class U2bC2V1 according to the ESHRE/ESGE classification). The patient presented with severe dyspareunia and dysmenorrhea. Imaging revealed a complex Müllerian anomaly and hysteroscopic treatment was agreed.
View Article and Find Full Text PDFDesign and development of Vaginal wall mimicking Poly (ε-caprolactone) based nanofibrous prosthetic mesh for pelvic organ prolapse: Evaluation of biocompatibility and antibacterial ability.
Biomed Mater
December 2024
Department of Chemical Engineering, Indian Institute of Technology - Bombay, Powai, Mumbai 400 076, Mumbai, Maharastra, 400076, INDIA.
Mechanical non-conformance of conventionally used transvaginal non-degradable meshes has led to complications like organ perforation, dyspareunia caused by mesh stiffness, and stress shielding. In this study, we have solved the dire need of mimicking the mechanical properties of vaginal wall by designing and developing a soft and elastic mesh made of polycaprolactone (PCL), citric acid modified polyethylene glycol (PEGC) and zinc oxide (ZnO) prepared through electrospinning and is tested in-vitro and in-vivo. Mesh containing 90:10:0.
View Article and Find Full Text PDFIntrauterine device (IUD) migration completely into the abdominal cavity and half into the bladder to form a stone: a case report and mini-review.
BMC Urol
December 2024
Department of Urology II, First Hospital of Jilin University, Changchun, Jilin, China.
The intrauterine device (IUD) is an important and highly effective means of contraception. Migration of the IUD, post implantation, out of the uterus is an infrequent complication, and its subsequent migration into the urinary bladder with formation of secondary bladder calculi, is even more infrequently reported. The authors report a 51 year old woman who had had her last child delivered via cesarean section 16 years ago.
View Article and Find Full Text PDFImpact of a Single Session of Hybrid Carbon Dioxide 10600 Nanometer and 1540 Nanometer Laser With Platelet-Rich Plasma Treatment in the Genital Area to Treat Female Sexual Dysfunction: A Pilot Study.
Cureus
December 2024
Department of Aesthetic and Anti-Aging Medicine, Central Medica Quirurgica, Mazatlan, MEX.
Background Female sexual dysfunction (FSD) affects a significant portion of the female population, negatively impacting quality of life. New therapeutic approaches, such as the combination of laser therapy and platelet-rich plasma (PRP), are being explored as potential treatments to enhance sexual function in affected women. Methods This original study involved 23 women aged 37 to 72, all diagnosed with varying degrees of FSD (mild, moderate, severe).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!